Mar 15, 2013 | Neuroscience, Research, School
The Center for Disease Control and Prevention has found that 1 in 88 people are affected by autism spectrum disorders (ASD), a disorder four times more common in boys than in girls. At the Seaver Autism Center for Research and Treatment, we are dedicated to discovering the biological causes of ASD and developing breakthrough treatments. Through molecular genetics, model systems, and experimental therapeutics, we strive to translate scientific research into optimal community care.
Our understanding of the genetic basis of autism and related conditions has changed recently. Based on discoveries made by large genetic consortia including the Autism Sequencing Consortium (ASC) which we lead, we now know that autism can be conceived of as having multiple independent causes, where in many cases the cause can be largely attributed to a specific genetic mutation. The ASC expects to identify half of all ASD genes in the next several years, leading to better diagnosis and treatment.
(more…)
Mar 15, 2013 | Neuroscience, Research, School
Marijuana (Cannabis sativa) is the illicit drug most commonly used by teenagers in the United States. Although cannabis is not as addictive as other substances, such as heroin and cocaine, cannabis-dependent individuals still greatly outnumber those reporting dependence on other illicit drugs and the number of people seeking treatment for cannabis dependence continues to increase yearly. Despite these facts, there is a growing perception, particularly in adolescents and young adults, that cannabis is ‘harmless’ and there is currently much debate as to whether cannabis should be legalized. Unfortunately, most of the discussion and policies being made regarding cannabis have been done without significant consideration of scientific data. Our studies directly address the question regarding the long-term impact on the brain as a consequence of cannabis exposure during adolescence, a period of dynamic brain development.
(more…)
Mar 13, 2013 | Neuroscience, Research, School
Is it possible to rapidly elevate the depressed mood? This has been a pressing question over the past 50 years because classic antidepressants, such as Prozac, are known to take weeks to reach clinical efficacy; combining medications to enhance antidepressant outcomes may take even longer, generally months. Mount Sinai has put forth enormous efforts to develop rapid treatments for major depressive disorder. Currently, ketamine treatment and deep brain stimulation are being investigated in clinical research and trials for treatment-resistant depressed patients at Mount Sinai.
Mount Sinai faculty has also been dedicated to the discovery of novel antidepressant treatments. As a faculty member in the Department of Pharmacology & Systems Therapeutics, as well as the Department of Neuroscience and Friedman Brain Institute, I am one of the neuroscientists working to reveal new drug and brain stimulation targets in animal models for the rapid treatment of depression.
(more…)
Mar 11, 2013 | Neuroscience, Research, School
The prevalence rate for depression in the United States is nearly 7%, yet standard antidepressants produce full remission in only 30-40% of patients. Even when treatment is effective, patients require 2-4 weeks to achieve the full therapeutic effects. Adding to the problem, there are currently no biological diagnostic tests to predict depression, forcing clinicians to diagnose based upon clusters of non-specific overlapping behavioral symptoms. Thus, in the Russo lab, we are interested in identifying novel biological targets to predict depression and treat it more rapidly and effectively.
(more…)
Mar 4, 2013 | Cardiology, Inside, Research, Your Health
A novel study of high-sugar consumption in Drosophila fruit flies is leading researchers at Icahn School of Medicine at Mount Sinai to a greater understanding of diabetes-related heart disease, and to therapeutic targets that could ultimately prevent arrhythmia, fibrosis, and other serious heart conditions.
The research—led by Ross L. Cagan, PhD, Professor of Developmental and Regenerative Biology, and Associate Dean of the Graduate School of Biomedical Sciences—was conducted in partnership with scientists from the Sanford-Burnham Medical Research Institute in California, and published online in the January 10 issue of PLOS Genetics.
(more…)
Mar 4, 2013 | Inside, Research
The Department of Psychiatry at Icahn School of Medicine at Mount Sinai has opened a new center to investigate and treat tics, obsessive compulsive disorder (OCD), and related disorders, which are estimated to affect more than 2 million people in the United States. The new center, at 1240 Park Avenue and 96th Street, serves patients in a clinical setting that is located down the hall from a research facility that will conduct clinical trials, genetic analysis, and functional brain imaging to learn more about the disorders.
Operated by the Division of Tic, Obsessive-Compulsive, and Related Disorders (DTOR), the center “is in the vanguard of academic psychiatry because it embraces the concept that tic disorders and OCD frequently overlap and are life-cycle disorders, not separate child and adult disorders,” says Wayne Goodman, MD, Chairman of the Department of Psychiatry at Icahn School of Medicine, and the Esther and Joseph Klingenstein Professor of Psychiatry. “We are among the first medical centers to put this important concept into practice in a way that improves patient care and research.”
(more…)
